slu-pp-332 and retatrutide together – REV-ERB Agonist for Circadian SLU-PP-332 – Peptidnova

GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonism: Working in concert with GLP-1, GIP activation further augments insulin release and contributes to feelings of satiety

Here is what we know as of March 2026: The biggest trial so far (called TRIUMPH-4) released results in December 2025

Long-term adherence Long-term adherence to semaglutide is a major challenge in the treatment of type 2 diabetes and weight management

Though not common, some side effects of these medications can be severe

In metabolic research, common readouts include body mass change, food intake, circulating biomarkers, adipose depot measurements, and indirect markers of substrate handling and energy use

Yes, you read that correctly